Novel RET Inhibitor BLU-667 Offers Promise for RET+ Advanced NSCLC
— · Default Digital Object Group · 2019
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Default Digital Object Group · OpenAlex · dataset · 2019
Abstract
The novel selective RET inhibitor BLU-667 demonstrated promising antitumor activity and was well tolerated in patients with RET fusion–positive advanced non–small cell lung cancer (NSCLC), according to a study presented on June 3 (Abstract 9008).
Open the resolved locator · 10.1200/adn.19.190332
Metadata licence: OpenAlex metadata (CC0)